Optimizing AAV Production Efficiency with CellVantage™-AAV: A Simple, Scalable Approach for Enhanced Upstream Yield

CellVantage™-AAV is Virica’s first off-the-shelf enhancer that drops into existing AAV workflows to increase upstream yield. Developed from high throughput screening of more than 15,000 molecules, it delivers 2 to 5 fold increase in genomic and functional AAV titers across multiple suspension HEK293-based platforms, including 2 to 4 fold in VPC 2.0 at 250 mL bioreactors scale and up to 2.5 fold in ReiThera’s ReiCell AAV, with more than 4 fold increase when combined with additional VSEs, validated at 2 L scale. It is easy to implement as a simple upstream additive to boost production and reduce costs rapidly. No tweaks, just titers.